Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
McKinsey
Boehringer Ingelheim
Colorcon
McKesson

Last Updated: January 19, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for Andrographolide


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Andrographolide?

Andrographolide is an investigational drug.

There have been 9 clinical trials for Andrographolide. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2016.

The most common disease conditions in clinical trials are Multiple Sclerosis, Bronchitis, and Acute Disease. The leading clinical trial sponsors are University of Chile, Jiangxi Qingfeng Pharmaceutical Co. Ltd., and Universidad Austral de Chile.

There is one US patent protecting this investigational drug and seven international patents.

Recent Clinical Trials for Andrographolide
TitleSponsorPhase
Efficacy of Ivermectin in COVID-19Bangkok Metropolitan Administration Medical College and Vajira HospitalPhase 1/Phase 2
To Compare the Efficacy and Tolerability of A. Paniculata/A. Chilensis in Individuals With URTIVedic Lifesciences Pvt. Ltd.Phase 3
HMPL004-6599 Phase I Dose-escalating StudyHutchison Medipharma LimitedPhase 1

See all Andrographolide clinical trials

Clinical Trial Summary for Andrographolide

Top disease conditions for Andrographolide
Top clinical trial sponsors for Andrographolide

See all Andrographolide clinical trials

US Patents for Andrographolide

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Andrographolide ⤷  Try it Free Method of diagnosing and treating cancer using B-catenin splice variants The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC) ⤷  Try it Free
Andrographolide ⤷  Try it Free Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC) ⤷  Try it Free
Andrographolide ⤷  Try it Free Use of inhibitors of Bruton'S tyrosine kinase (Btk) Pharmacyclics LLC (Sunnyvale, CA) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
McKinsey
Boehringer Ingelheim
Colorcon
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.